Sumitomo Pharma Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Sumitomo Pharma Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Sumitomo Pharma Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Sumitomo Pharma Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sumitomo Pharma Co Ltd (Sumitomo Pharma), formerly Sumitomo Dainippon Pharma Co Ltd, develops, manufactures, sells, imports and exports pharmaceutical products. The company drugs are focused on major therapeutic areas which include regenerative diseases, oncology, psychiatry and neurology, and infectious diseases. It also offers veterinary medicines for companion animals, primarily dogs, and cats, as well as for livestock such as cattle, swine, poultry, horses, and aquaculture fish. The company offers food additives, chemical product materials, food ingredients, and other products. Sumitomo Pharma has research laboratories and manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in North America, Europe, and Asia Pacific. Sumitomo Pharma is headquartered in Chuo-ku, Osaka, Japan.
Headquarters
Japan
Address
2-6-8, Dosho-Machi, Chuo-Ku, Osaka, 541-0045
Website
www.sumitomo-pharma.co.jp
Telephone
81 6 62035321
No of Employees
3,832
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4506 (TYO)
Revenue (2024)
$2.9B
13.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2025)
XYZ
352.2%
(2025 vs 2024)
Market Cap*
$4.1B
Net Profit Margin (2025)
XYZ
297.6%
(2025 vs 2024)
* As of and is in US$
Sumitomo Pharma Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Pharmaceuticals: | Service: | Gemtesa |
| Oncology Drugs | Contract Manufacturing | Latuda |
| Psychiatry and Neurology Drugs | Equa | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In October, the company entered into a promotion collaboration agreement with Novo Nordisk Pharma, for Ugovi subcutaneous injection, a once-weekly subcutaneously administered GLP-1 receptor agonist indicated for the treatment of obesity, in Japan. |
| 2025 | Corporate Changes/Expansions | In August, the company announced the completion of regenerative medicine and cellular medicine manufacturing facility know as the Center for Regenerative Medicine and Future Therapy (CRAFT). |
| 2025 | Regulatory Approval | In June, the company's subsidiary Sumitomo Pharma America Inc received Fast Track Designation from the US Food and Drug Administration (FDA) for nuvisertib, an investigational anti-cancer agent, for the treatment of patients with intermediate- or high-risk myelofibrosis. |
Competitor Comparison
| Key Parameters | Sumitomo Pharma Co Ltd | Takeda Pharmaceutical Co Ltd | Astellas Pharma Inc | Daiichi Sankyo Co Ltd | Chugai Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Osaka | Chuo-Ku | Chuo-Ku | Chuo-Ku | Chuo-Ku |
| State/Province | Osaka | Tokyo | Tokyo | Tokyo | Tokyo |
| No. of Employees | 3,832 | 47,455 | 13,643 | 19,765 | 7,872 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Toru Kimura | Chief Executive Officer; Director; President | Executive Board | 2024 | 66 |
| Tsutomu Nakagawa | Chief Executive Officer - Sumitomo Pharma America Inc; Director; Managing Executive Officer - North America Business; President - Sumitomo Pharma America Inc | Executive Board | 2024 | 58 |
| Motoyuki Sakai | Director; Executive Vice President - Global Corporate Strategy, Global Finance, Legal & Compliance, Intellectual Property, Human Resources, External Affairs, Corporate Governance, IT Management & Data Analytics Administration | Executive Board | 2024 | 65 |
| Hideyuki Harada | Head - Japan Business Unit; Head - Supply Chain Division; Managing Executive Officer-Supply Chain Division; Senior Vice President | Senior Management | 2024 | - |
| Koichi Kozuki | Deputy Head-Japan Business Unit; Executive Officer-Corporate Regulatory Compliance & Quality Assurance Division; Head - Corporate Regulatory Compliance & Quality Assurance Division; Senior Vice President | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer